QuidelOrtho Announces Availability of QUICKVUE™ Influenza + SARS Test for Professional Use

About this update from Quidelortho Corporation

SAN DIEGO , Sept. 22, 2025 /PRNewswire/ -- Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (Nasdaq: QDEL) (" QuidelOrtho "), a leading global provider of innovative in vitro diagnostic technologies, is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized hospital labs. The QUICKVUE Influenza + SARS Test is designed to deliver rapid, simultaneous detection and differentiation of influenza A, influenza B and SARS-CoV-2 antigens from a single patient sample, providing results in as fast as 10 minutes. This capability can help clinicians distinguish between COVID-19 and seasonal flu infections, which present similar symptoms, enabling timely treatment decisions and improved patient outcomes. Key Features and Benefits: Triple Detection Capability : Differentiates influenza A/B and COVID-19 in one test. Fast Results : Clear results available in as fast as 10 minutes at the point of care. Professional Use : Designed for CLIA-waived and moderate/high-complexity lab settings. Efficient Workflow : Easy-to-collect nasal swab, streamlined processing and clear result window. Affordable Access: Cost-effective visual combo test. "Physician office labs and urgent care centers are on the front lines of respiratory illness diagnosis. With the QUICKVUE Influenza + SARS Test, we're equipping healthcare providers with a reliable, affordable and efficient tool to differentiate between COVID-19 and influenza in minutes," said Tammi Ranalli , PhD, Senior Vice President, Molecular Diagnostics and Point of Care Business Units, QuidelOrtho . "This innovation reflects QuidelOrtho's commitment to supporting healthcare professionals with cost-effective solutions that streamline clinical decisions and help manage seasonal surges in respiratory infections." The launch of the QUICKVUE Influenza + SARS Test expands QuidelOrtho's portfolio of respiratory solutions, including the SOFIA ™ 2 Flu + SARS Antigen FIA, by offering a visually read option alongside QuidelOrtho's instrumented version and reinforces QuidelOrtho's market leadership in point-of-care respiratory testing. The QUICKVUE Influenza + SARS Test is available in the United States through QuidelOrtho's existing distribution channels and is not intended for in-home use. About QuidelOrtho Corporation With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care. For more information, visit www.quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X. Investor Contact: Juliet Cunningham Vice President, Investor Relations [email protected] Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications [email protected] View original content to download multimedia: https://www.prnewswire.com/news-releases/quidelortho-announces-availability-of-quickvue-influenza--sars-test-for-professional-use-302561981.html SOURCE QuidelOrtho Corporation

View stock analysis, news, and events for Quidelortho Corporation